Creativ-Ceutical is now part of our team. Learn more here.
Log in or register to see all Alerts
Log in Register
Market Access Alerts >December 2021>England
New HTA Decisions in England
December 2021
Drug name
SAXENDA® (liraglutide)
Company
Novo Nordisk
Decision date
//
About PHMR
Therapeutic area
Diabetes and other endocrinal, nutritional and metabolic conditions
Therapeutic sub area
Obesity
Decision
Not recommended
Indication
Terminated appraisal
Decision Detail
NICE is unable to make a recommendation about the use in the NHS of liraglutide for managing obesity in people aged 12 to 17 years. This is because Novo Nordisk does not intend to provide an evidence submission for the appraisal. Novo Nordisk considers that there is not enough evidence to provide an evidence submission for this appraisal. NICE will review the position if the company decides that it wants to make an evidence submission.
Summary


PHMR
Berkeley Works
Berkley Grove
London
NW1 8XY

+44 (0)20 3432 7450

info@phmr.com


 Understanding Payers

 Generating Evidence

 Developing Strategies

 Communicating Value

 Market Access Alerts

 Careers

 About us

 Contact us

 Cookie policy

 Privacy